Find policies, billing codes, payers, states, and providers
CPT 86619: Borrelia Relapsing Fever Antibody Immunoassay
CPT code 86619 denotes a laboratory immunoassay to detect antibodies to Borrelia species that cause relapsing fever. As a targeted serologic diagnostic, this code supports clinical decision-making for suspected relapsing fever and public health surveillance of Borrelia infections. Nationally, accurate coding for specialized infectious disease testing affects laboratory reporting, reimbursement consistency, and epidemiologic tracking.
Key payers in this review include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage patterns, coding and billing considerations, and clinical context for when testing is appropriate. Benchmarks and reimbursement trends are summarized where available; readers will also find notes on typical sites of service and the laboratory workflow implications for ordering and reporting results.
Readers will learn: the clinical purpose of the assay, where the test is commonly performed, which payers are typically involved in coverage discussions, and what informational gaps exist in the available input. Data not available in the input is indicated explicitly in relevant sections of the full publication.
Customize your policy alerts
Sign up for cpt 86619 policy alerts
Get alerted when payer policies referencing 86619 are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 86619 describes an immunoassay performed by a laboratory analyst to detect antibodies to Borrelia species associated with relapsing fever. The test evaluates a patient’s blood specimen for serologic evidence of infection by Borrelia organisms that cause relapsing fever.
Service type: Laboratory diagnostic immunoassay
Typical site of service: Clinical or hospital laboratory, reference laboratory, or other outpatient laboratory setting